INSUBCONTINENT EXCLUSIVE:
Pharma major Sun Pharmaceutical on Tuesday posted a consolidated loss of Rs 218.82 crore for quarter ended September 30, on one-time loss of
Rs 1,214.38 crore with respect to Modafinil antitrust litigation.
Analysts in an ET NOW poll had estimated a profit of Rs 975 crore.
The
drug firm had posted a profit of Rs 912.12 crore in the corresponding quarter last year.
Consolidated total revenue increased 4.32 per cent
year-on-year to Rs 6,937.63 crore during the quarter under review against Rs 6,650.34 crore in the same period last year.
Total expenditure
jumped to Rs 5,962.46 crore in Q2FY19 over Rs 5,790.82 crore in Q2FY18.
The company announced its financial results post market hours
Earlier in the session, shares of Sun Pharmaceuticals closed 4.72 per cent down at Rs 561.70, while the BSE Sensex gained 0.95 per cent to
35,144.49.
Ebitda rose to Rs 1,530.90 crore during the quarter under review against Rs 376 crore last year.
For the quarter ended September
30, margins came in at 22.10 per cent against 19.90 per cent last year.
